3. Acquisitions Shape Pharmaceuticals On April 14, 2014 ( the acquisition date ), we acquired by merger 100% of Shape Pharmaceuticals. Shape Pharmaceuticals was a development stage pharmaceutical company developing SHAPE, a novel, tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma (CTCL). The acquisition added a second clinical-stage oncology compound to the TetraLogic portfolio. The acquisition date fair value of consideration transferred totaled $13.0 million, all of which was in cash. The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date: Allocation of purchase price Cash and cash equivalents $ 71,792 Other current assets 320,464 Accounts payable (138,645) Deferred taxes (14,303,589) Contingent consideration (22,587,339) Legal expenses 121,873 Indefinite-lived intangible assets 35,230,516 Goodwill 14,326,396 Total purchase price $ 13,041,468 The purchase price allocation is being finalized based on fair values of the acquired assets and liabilities. The intangible assets acquired represent indefinite-lived intangible assets relating to the technology acquired from Shape Pharmaceuticals. These intangibles will not be amortized until FDA approval has been obtained for a product that uses this technology. Goodwill results primarily from the recognition of deferred tax liabilities in connection with the acquisition. There is no goodwill recognized or deductible for tax purposes. The acquisition of Shape Pharmaceuticals includes a contingent consideration arrangement that may require us to pay additional consideration in the form of milestone payments and tiered royalty payments upon commercialization. We currently estimate that the milestone payments will occur between 2016 and 2020. The range of undiscounted amounts that we could be required to pay under our agreement for the milestone payments is between zero and $64.5 million. We determined the fair value of the liability for the continge